04 Feb 2010
Elevated cytosolic DA levels have been shown to result in increased neurotoxicity in cellular models of PD (Mosharov et al., 2009). In a new study published in the Journal of Neuroscience Research, ... 
06 Jan 2010
The posting by Dr. Levitan does not substantively address any of the core concerns expressed in our recent commentary about the Putzier et al. paper. Again, the fundamental issue is whether high ... 
04 Jan 2010
We were pleased that Dr. Williams noted the significance of Putzier et al. (2009), which showed that Cav1.3 channels support nigral dopamine neuron pacemaker activity and amplify bursts by virtue of ... 
Responses: 1
19 Dec 2009
Dr. Williams has written an informative and insightful assessment of some of the recent work bearing on calcium and the selective vulnerability of substantia nigra pars compacta (SNc) dopaminergic ... 
15 Dec 2009
Three recent papers published in the Journal of Neuroscience address the mechanisms that underlie the activity of dopamine neurons in the Substantia Nigra.  The interest in this work stems from ... 
Cognitive Symptoms
28 Oct 2009
Several studies have shown that cognitive reinforcement learning processes are altered in Parkinson's disease, and are particularly sensitive to effects of dopaminergic medication. While off ... 
Hot Topics@SfN 2009
26 Oct 2009
The SfN minisymposium “Protein Networks Regulating Dopamine Homeostasis” on October 20th, co-chaired by Ruth G. Perez and Gonzalo Torres of the University of Pittsburgh, revealed novel ... 
Hot Topics@SfN 2009
18 Oct 2009
Enhanced signaling via dopamine receptors has been suggested to contribute to L-DOPA-induced dyskinesia (LID) in Parkinson’s disease. Dopamine receptors are desensitized via ... 
Hot Topics@SfN 2009
13 Oct 2009
The neurotransmitter dopamine (DA) contributes significantly to movement, reward, mood, cognition, and addiction.  As such, DA regulation is a critical factor in wellness and DA dysregulation ... 
Responses: 1